+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Clostridium Difficile Treatment Market by Treatment Type, Route of Administration, Patient Age Group, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6014676
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Clostridium Difficile Treatment Market grew from USD 8.82 billion in 2023 to USD 9.41 billion in 2024. It is expected to continue growing at a CAGR of 6.89%, reaching USD 14.07 billion by 2030.

The Clostridium Difficile treatment market encompasses a variety of therapies aimed at addressing infections caused by the bacterium C. difficile, which can lead to conditions ranging from mild diarrhea to life-threatening inflammation of the colon. The necessity for treatment is underscored by the bacterium's high incidence among hospitalized patients and its potential for recurrence, making effective and diverse therapeutic strategies crucial. Applications include antibiotics, probiotics, fecal microbiota transplantation (FMT), and novel pipeline drugs targeting toxin neutralization and immune system modulation. End-use sectors are primarily healthcare settings, including hospitals and clinics, which face the daunting task of managing and preventing these infections among diverse patient populations.

Market growth is influenced by the rising prevalence of C. difficile infections, heightened awareness and diagnosis, and developments in innovative treatment methodologies. Recent trends indicate potential opportunities in biotherapeutics, particularly FMT and other microbiome-based treatments, driven by increasing interest in gut health and personalized medicine. Companies can leverage these opportunities by investing in rigorous clinical trials to establish efficacy and safety, expanding partnerships for collaborative research, and securing regulatory approvals to streamline pathways to market.

However, challenges persist, including stringent regulatory hurdles, high cost of treatment development, and the complexity of conducting robust clinical trials given the recurrence nature of these infections. Furthermore, antibiotic resistance and limited treatment efficacy in recurrent cases pose critical concerns that may hinder market potential.

Innovations may be most beneficial in areas such as the development of non-antibiotic treatments to minimize resistance risk, advancement of digital health tools to monitor patient outcomes, and precision medicine approaches, which can tailor treatments to individual patient profiles. The nature of this market is highly dynamic, driven by a blend of clinical needs and technological advancements. Insights indicate that companies focusing on an integrated approach - combining cutting-edge science, strategic partnerships, and a patient-centric model - are likely to lead in this evolving landscape.

Understanding Market Dynamics in the Clostridium Difficile Treatment Market

The Clostridium Difficile Treatment Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of Clostridium difficile infection
    • Focus on preventive strategies and probiotics
    • Increased healthcare awareness and initiatives to treat clostridium difficile infection
  • Market Restraints
    • Antibiotic resistance and recurrence rates
  • Market Opportunities
    • Development of targeted and advanced therapies
    • Advancements in diagnostic tools and techniques
  • Market Challenges
    • Complexity of accurate diagnosis and limitations in regulatory compliance

Exploring Porter’s Five Forces for the Clostridium Difficile Treatment Market

Porter’s Five Forces framework further strengthens the insights of the Clostridium Difficile Treatment Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Clostridium Difficile Treatment Market

External macro-environmental factors deeply influence the performance of the Clostridium Difficile Treatment Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Clostridium Difficile Treatment Market

The Clostridium Difficile Treatment Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Clostridium Difficile Treatment Market

The Clostridium Difficile Treatment Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Clostridium Difficile Treatment Market

The Clostridium Difficile Treatment Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Clostridium Difficile Treatment Market, highlighting leading vendors and their innovative profiles. These include Acurx Pharmaceuticals, Inc., Aridis Pharmaceuticals, Inc., Astellas Pharma Inc., AstraZeneca PLC, GlaxoSmithKlinePLC, Immuron Limited, Merck & Co., Inc., Mylan N.V., Pfizer, Inc., Rebiotix Inc, Roche Holding AG, Seres Therapeutics, Inc., Summit Therapeutics, Inc., Synthetic Biologics, Inc., Thermo Fisher Scientific, Inc., Trinity Biotech PLC, and Vedanta Biosciences, Inc..

Market Segmentation & Coverage

This research report categorizes the Clostridium Difficile Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Treatment Type
    • Antibiotics Treatment
      • Fidaxomicin
      • Metronidazole
      • Vancomycin
    • Non-Antibiotic Treatment
      • Fecal Microbiota Transplantation
      • Probiotics
  • Route of Administration
    • Oral
    • Parenteral
  • Patient Age Group
    • Adults
    • Geriatric
    • Pediatric
  • End-User
    • Home Healthcare
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of Clostridium difficile infection
5.1.1.2. Focus on preventive strategies and probiotics
5.1.1.3. Increased healthcare awareness and initiatives to treat clostridium difficile infection
5.1.2. Restraints
5.1.2.1. Antibiotic resistance and recurrence rates
5.1.3. Opportunities
5.1.3.1. Development of targeted and advanced therapies
5.1.3.2. Advancements in diagnostic tools and techniques
5.1.4. Challenges
5.1.4.1. Complexity of accurate diagnosis and limitations in regulatory compliance
5.2. Market Segmentation Analysis
5.2.1. Treatment Type: Growing demand for Fidaxomicin to ensure low recurrence rates and minimal disruption to the gut microbiome
5.2.2. End User: Increasing availability of clostridium difficile treatment across hospitals and clinics
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Clostridium Difficile Treatment Market, by Treatment Type
6.1. Introduction
6.2. Antibiotics Treatment
6.2.1. Fidaxomicin
6.2.2. Metronidazole
6.2.3. Vancomycin
6.3. Non-Antibiotic Treatment
6.3.1. Fecal Microbiota Transplantation
6.3.2. Probiotics
7. Clostridium Difficile Treatment Market, by Route of Administration
7.1. Introduction
7.2. Oral
7.3. Parenteral
8. Clostridium Difficile Treatment Market, by Patient Age Group
8.1. Introduction
8.2. Adults
8.3. Geriatric
8.4. Pediatric
9. Clostridium Difficile Treatment Market, by End-User
9.1. Introduction
9.2. Home Healthcare
9.3. Hospitals & Clinics
10. Americas Clostridium Difficile Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Clostridium Difficile Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Clostridium Difficile Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Vedanta Biosciences advances VE303 in phase III trial to combat recurrent c. difficile infections, eyes market approval, and strategic investments
13.3.2. Acurx Pharmaceuticals advances Ibezapolstat to phase 3 clinical trials following FDA end-of-phase 2 approval for clostridium difficile treatment
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. CLOSTRIDIUM DIFFICILE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. CLOSTRIDIUM DIFFICILE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CLOSTRIDIUM DIFFICILE TREATMENT MARKET DYNAMICS
TABLE 7. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY FIDAXOMICIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY FECAL MICROBIOTA TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 49. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 51. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 53. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 57. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 79. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 80. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 89. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 97. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 101. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 105. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 110. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 111. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 123. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 134. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 135. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 137. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 151. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 152. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 153. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 154. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 159. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 160. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 162. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 165. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 166. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 171. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 172. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 174. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 176. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 177. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 178. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 188. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 189. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 190. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 192. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 200. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 205. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 206. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 207. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 208. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 210. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 213. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 214. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 216. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 219. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 220. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 222. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 242. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 243. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 244. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 259. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 261. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 262. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 264. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS TREATMENT, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY NON-ANTIBIOTIC TREATMENT, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 278. CLOSTRIDIUM DIFFICILE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Clostridium Difficile Treatment Market, which are profiled in this report, include:
  • Acurx Pharmaceuticals, Inc.
  • Aridis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • GlaxoSmithKlinePLC
  • Immuron Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Pfizer, Inc.
  • Rebiotix Inc
  • Roche Holding AG
  • Seres Therapeutics, Inc.
  • Summit Therapeutics, Inc.
  • Synthetic Biologics, Inc.
  • Thermo Fisher Scientific, Inc.
  • Trinity Biotech PLC
  • Vedanta Biosciences, Inc.

Methodology

Loading
LOADING...

Table Information